Androgen receptor gene rearrangements: New perspectives on prostate cancer progression

Current Drug Targets

Volumn 14, Issue 4, 2013, Pages 441-449

  Brand, Lucas J ^a,b   Dehm, Scott M ^b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Alternative splicing; Androgen receptor; Castration resistance; Genomic rearrangement; Prostate cancer

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ENZALUTAMIDE; MESSENGER RNA; SMALL INTERFERING RNA;

ALTERNATIVE RNA SPLICING; ANDROGEN DEPRIVATION THERAPY; CANCER GROWTH; GAIN OF FUNCTION MUTATION; GENE DOSAGE; GENE LOCUS; GENE REARRANGEMENT; HUMAN; NUCLEAR LOCALIZATION SIGNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA INTERFERENCE;

ANDROGENS; DISEASE PROGRESSION; GENE REARRANGEMENT; GENOMIC STRUCTURAL VARIATION; HUMANS; MALE; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN;

EID: 84876734860     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111314040005     Document Type: Review

References (82)

1. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308.
2. Claessens F, Denayer S, Van Tilborgh N, et al. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl Recept Signal 2008; 6: e008.
3. Shaffer PL, Jivan A, Dollins DE, et al. Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci USA 2004; 101: 4758-63.
4. Wilson JD. The role of 5alpha-reduction in steroid hormone physiology. Reprod Fertil Dev 2001; 13: 673-8.
5. Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alphareductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 2008; 179: 1235-42.
6. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 1997; 18: 306-60.
7. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002; 9: 601-10.
8. Wang Q, Carroll JS, Brown M. Spatial and Temporal Recruitment of Androgen Receptor and Its Coactivators Involves Chromosomal Looping and Polymerase Tracking. Mol Cell 2005; 19: 631-42.
9. Makkonen H, Kauhanen M, Paakinaho V, et al. Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers. Nucleic Acids Res 2009; 37: 4135-48.
10. Wu D, Zhang C, Shen Y, Nephew KP, Wang Q. Androgen receptor-driven chromatin looping in prostate cancer. Trends Endocrinol Metab 2011; 22: 474-80.
11. Agoulnik IU, Weigel NL. Coactivator selective regulation of androgen receptor activity. Steroids 2009; 74: 669-74.
12. Naar AM, Lemon BD, Tjian R. Transcriptional coactivator complexes. Annu Rev Biochem 2001; 70: 475-501.
13. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007; 28: 778-808.
14. Pereira de Jesus-Tran K, Cote PL, Cantin L, et al. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci 2006; 15: 987-99.
15. Knudsen KE, Scher HI. Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer. Clin Cancer Res 2009; 15: 4792-8.
16. Matias PM, Donner P, Coelho R, et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 2000; 275: 26164-71.
17. Sack JS, Kish KF, Wang C, et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci 2001; 98: 4904-9.
18. Jasuja R, Ulloor J, Yengo CM, et al. Kinetic and Thermodynamic Characterization of Dihydrotestosterone-Induced Conformational Perturbations in Androgen Receptor Ligand-Binding Domain. Mol Endocrinol 2009; 23: 1231-41.
19. He B, Gampe RT, Kole AJ, et al. Structural Basis for Androgen Receptor Interdomain and Coactivator Interactions Suggests a Transition in Nuclear Receptor Activation Function Dominance. Mol Cell 2004; 16: 425-38.
20. Watanabe C, Watanabe H, Tanaka S. An interpretation of positional displacement of the helix12 in nuclear receptors: Preexistent swing-up motion triggered by ligand binding. Biochim Biophys Acta Proteins Proteom 2010; 1804: 1832-40.
21. Dubbink HJ, Hersmus R, Verma CS, et al. Distinct Recognition Modes of FXXLF and LXXLL Motifs by the Androgen Receptor. Mol Endocrinol 2004; 18: 2132-50.
22. Saporita AJ, Zhang Q, Navai N, et al. Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J Biol Chem 2003; 278: 41998-2005.
23. Estebanez-Perpina E, Arnold LA, Nguyen P, et al. A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci 2007; 104: 16074-9.
24. Grosdidier S, Carbo LR, Buzon V, et al. Allosteric Conversation in the Androgen Receptor Ligand-Binding Domain Surfaces. Mol Endocrinol 2012; 26: 1078-90.
25. Buzon V, Carbo LR, Estruch SB, et al. A conserved surface on the ligand binding domain of nuclear receptors for allosteric control. Mol Cel Endocrinol 2012; 348: 394-402.
26. De Leon JT, Iwai A, Feau C, et al. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci 2011; 108: 11878-83.
27. Joseph JD, Wittmann BM, Dwyer MA, et al. Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. Proc Natl Acad Sci 2009; 106: 12178-83.
28. Axerio-Cilies P, Lack NA, Nayana MRS, et al. Inhibitors of Androgen Receptor Activation Function-2 (AF2) Site Identified through Virtual Screening. J Med Chem 2011; 54: 6197-205.
29. Siegel R, Naishadham D, Jemal A. Cancer statistics. Cancer J. Clin 2012; 62: 10-29.
30. O'Mahony OA, Steinkamp MP, Albertelli MA, et al. Profiling Human Androgen Receptor Mutations Reveals Treatment Effects in a Mouse Model of Prostate Cancer. Mol Cancer Res 2008; 6: 1691-701.
31. Steinkamp MP, O'Mahony OA, Brogley M, et al. Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy. Cancer Res 2009; 69: 4434-42.
32. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68: 6407-15.
33. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011; 8: 12-23.
34. Lamont KR, Tindall DJ. Minireview: alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 2011; 25: 897-907.
35. Nadiminty N, Gao AC. Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World J Urol 2012; 30: 287-95.
36. Tran C, Ouk S, Clegg NJ, et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer. Science 2009; 324: 787-90.
37. Attard G, Reid AHM, Olmos D, de Bono JS. Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven. Cancer Res 2009; 69: 4937-40.
38. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and Increased Survival in Metastatic Prostate Cancer. N Engl J Med 2011; 364: 1995-2005.
39. Scher HI, Fizazi K, Saad F, et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med 2012; 367: 1187-97.
40. Payton S. Prostate cancer: MDV3100 has antitumor activity in castration-resistant disease. Nat Rev Urol 2010; 7: 300.
41. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1/2 study. Lancet 2010; 375: 1437-46.
42. Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer 2011; 18: R183-R96.
43. Tepper CG, Boucher DL, Ryan PE, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002; 62: 6606-14.
44. Céraline J, Cruchant MD, Erdmann E, et al. Constitutive activation of the androgen receptor by a point mutation in the hinge region: A new mechanism for androgen-independent growth in prostate cancer. Int J Cancer 2004; 108: 152-7.
45. Libertini SJ, Tepper CG, Rodriguez V, et al. Evidence for Calpain-Mediated Androgen Receptor Cleavage as a Mechanism for Androgen Independence. Cancer Res 2007; 67: 9001-5.
46. Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance. Cancer Res 2008; 68: 5469-77.
47. Guo Z, Yang X, Sun F, et al. A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth. Cancer Res 2009; 69: 2305-13.
48. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69: 16-22.
49. Marcias G, Erdmann E, Lapouge G, et al. Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Hum Mutat 2010; 31: 74-80.
50. Sun S, Sprenger CCT, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120: 2715-30.
51. Chan SC, Li Y, Dehm SM. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem 2012; 287: 19736-49.
52. Hu R, Lu C, Mostaghel EA, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012; 72: 3457-62.
53. Zhou ZX, Sar M, Simental JA, et al. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J Biol Chem 1994; 269: 13115-23.
54. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. Science 2005; 310: 644-8.
55. Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010; 16: 793-8.
56. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-20.
57. Pflueger D, Terry S, Sboner A, et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res 2011; 21: 56-67.
58. Rubin MA, Maher CA, Chinnaiyan AM. Common Gene Rearrangements in Prostate Cancer. J Clin Oncol 2011; 29: 3659-68.
59. Reid AHM, Attard G, Brewer D, et al. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Mod Pathol 2012; 25: 902-10.
60. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer. Cancer Res 2006; 66: 8337-41.
61. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008; 27: 253-63.
62. Fine SW, Gopalan A, Leversha MA, et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with highgrade morphological features. Mod Pathol 2010; 23: 1325-33.
63. Saramaki OR, Harjula AE, Martikainen PM, et al. TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis. Clin Cancer Res 2008; 14: 3395-400.
64. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy. Cancer Res 2009; 69: 1400-6.
65. Grasso CS, Wu Y-M, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-43.
66. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18: 11-22.
67. Li Y, Alsagabi M, Fan D, et al. Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression. Cancer Res 2011; 71: 2108-17.
68. Watson PA, Chen YF, Balbas MD, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci 2010; 107: 16759-65.
69. Li Y, Hwang TH, Oseth LA, et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 2012; 31: 4759-67.
70. Hornberg E, Ylitalo EB, Crnalic S, et al. Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival. PLoS ONE 2011; 6: e19059.
71. Zhang X, Morrissey C, Sun S, et al. Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases. PLoS ONE 2011; 6: e27970.
72. Alen P, Claessens F, Verhoeven G, et al. The Androgen Receptor Amino-Terminal Domain Plays a Key Role in p160 Coactivator-Stimulated Gene Transcription. Mol Cell Biol 1999; 19: 6085-97.
73. Bevan CL, Hoare S, Claessens F, et al. The AF1 and AF2 Domains of the Androgen Receptor Interact with Distinct Regions of SRC1. Mol Cell Biol 1999; 19: 8383-92.
74. Christiaens V, Bevan CL, Callewaert L, et al. Characterization of the Two Coactivator-interacting Surfaces of the Androgen Receptor and Their Relative Role in Transcriptional Control. J Biol Chem 2002; 277: 49230-7.
75. Dehm SM, Tindall DJ. Ligand-independent Androgen Receptor Activity Is Activation Function-2-independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer Cells. J Biol Chem 2006; 281: 27882-93.
76. Dehm SM, Regan KM, Schmidt LJ, Tindall DJ. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells. Cancer Res 2007; 67: 10067-77.
77. Chamberlain NL, Whitacre DC, Miesfeld RL. Delineation of two distinct type 1 activation functions in the androgen receptor aminoterminal domain. J Biol Chem 1996; 271: 26772-8.
78. Zhu P, Baek SH, Bourk EM, et al. Macrophage/Cancer Cell Interactions Mediate Hormone Resistance by a Nuclear Receptor Derepression Pathway. Cell 2006; 124: 615-29.
79. Callewaert L, Van Tilborgh N, Claessens F. Interplay between Two Hormone-Independent Activation Domains in the Androgen Receptor. Cancer Res 2006; 66: 543-53.
80. Hilser VJ, Thompson EB. Structural Dynamics, Intrinsic Disorder, and Allostery in Nuclear Receptors as Transcription Factors. J Biol Chem 2011; 286: 39675-82.
81. Andersen RJ, Mawji NR, Wang J, et al. Regression of castraterecurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010; 17: 535-46.
82. Meimetis LG, Williams DE, Mawji NR, et al. Niphatenones, Glycerol Ethers from the Sponge Niphates digitalis Block Androgen Receptor Transcriptional Activity in Prostate Cancer Cells: Structure Elucidation, Synthesis, and Biological Activity. J Med Chem 2012; 55: 503-14.